XML 59 R21.htm IDEA: XBRL DOCUMENT
v3.25.2

Stock Purchase and Award Plans | 12 Months Ended
--- | ---
Apr. 25, 2025
Share-Based Payment Arrangement [Abstract] |
Stock Purchase and Award Plans | Stock Purchase and Award Plans In fiscal year 2025, the Company granted stock awards under the 2021 Medtronic plc Long Term Incentive Plan (2021 Plan). The 2021 Plan provides for the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other stock and cash-based awards. At April 25, 2025, there were approximately 67 million shares available for future grants under the 2021 Plan. Stock-Based Compensation Expense The following table presents the components and classification of stock-based compensation expense recognized for stock options, restricted stock, performance share units, and employee stock purchase plan (ESPP) in fiscal years 2025, 2024, and 2023:
| Fiscal Year
(in millions) | 2025 |  | 2024 |  | 2023
Stock options | $ | 66 |  |  | $ | 76 |  |  | $ | 77 |
Restricted stock | 216 |  |  | 184 |  |  | 166 |
Performance share units | 111 |  |  | 97 |  |  | 74 |
Employee stock purchase plan | 35 |  |  | 36 |  |  | 38 |
Total stock-based compensation expense | $ | 429 |  |  | $ | 393 |  |  | $ | 355 |
Cost of products sold | $ | 46 |  |  | $ | 35 |  |  | $ | 36 |
Research and development expense | 52 |  |  | 47 |  |  | 39 |
Selling, general, and administrative expense | 331 |  |  | 310 |  |  | 280 |
Total stock-based compensation expense | 429 |  |  | 393 |  |  | 355 |
Income tax benefits | (70) |  |  | (64) |  |  | (60) |
Total stock-based compensation expense, net of tax | $ | 358 |  |  | $ | 329 |  |  | $ | 295 |
Stock Options Options are granted at the exercise price, which is equal to the closing price of the Company’s ordinary shares on the grant date. The majority of the Company’s options are non-qualified options with a ten-year life and a four-year ratable vesting term. The Company uses the Black-Scholes option pricing model (Black-Scholes model) to determine the fair value of stock options at the grant date. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company’s stock price, and expected dividends. Expected volatility is based on a blend of historical volatility and an implied volatility of the Company’s ordinary shares. Implied volatility is based on market traded options of the Company’s ordinary shares. The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model:
| Fiscal Year
| 2025 |  | 2024 |  | 2023
Weighted average fair value of options granted | $ | 16.43 |  |  | $ | 18.49 |  |  | $ | 17.76 |
Assumptions used: |  |  |  |  |
Expected life (years) | 6.1 |  | 6.1 |  | 6.0
Risk-free interest rate | 4.07 | % |  | 4.16 | % |  | 2.70 | %
Volatility | 24.47 | % |  | 24.29 | % |  | 24.05 | %
Dividend yield | 3.48 | % |  | 3.18 | % |  | 2.92 | %
The following table summarizes stock option activity during fiscal year 2025:
| Options (in thousands) |  | Wtd. Avg. Exercise Price |  | Wtd. Avg. Remaining Contractual Term (in years) |  | Aggregate Intrinsic Value (in millions)
Outstanding at April 26, 2024 | 32,339 |  |  | $ | 93.32 |  |  |  |  |
Granted | 3,414 |  |  | 80.61 |  |  |  |  |
Exercised | (6,058) |  |  | 77.30 |  |  |  |  |
Expired/Forfeited/Cancelled | (1,928) |  |  | 96.31 |  |  |  |  |
Outstanding at April 25, 2025 | 27,766 |  |  | 95.04 |  |  | 5.2 |  | $ | 22 |
Expected to vest at April 25, 2025 | 7,764 |  |  | 88.49 |  |  | 8.3 |  | 14 |
Exercisable at April 25, 2025 | 19,467 |  |  | 97.93 |  |  | 3.9 |  | 7 |
The following table summarizes the total cash received from the issuance of new shares upon stock option award exercises, the total intrinsic value of options exercised, and the related tax benefit during fiscal years 2025, 2024, and 2023:
| Fiscal Year
(in millions) | 2025 |  | 2024 |  | 2023
Cash proceeds from options exercised | $ | 305 |  |  | $ | 78 |  |  | $ | 77 |
Intrinsic value of options exercised | 66 |  |  | 28 |  |  | 42 |
Tax benefit related to options exercised | 14 |  |  | 6 |  |  | 9 |
Unrecognized compensation expense related to outstanding stock options at April 25, 2025 was $66 million and is expected to be recognized over a weighted average period of 2.3 years. Restricted Stock Restricted stock units are expensed over the vesting period and are subject to forfeiture if employment terminates prior to the lapse of the restrictions. The expense recognized for restricted stock units is equal to the grant date fair value, which is equal to the closing stock price on the date of grant. The majority of the Company's restricted stock units either have a four-year ratable vesting term or cliff vest after three years. Restricted stock units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on restricted stock units during the vesting period. The following table summarizes restricted stock activity during fiscal year 2025:
| Units (in thousands) |  | Wtd. Avg. Grant Price
Nonvested at April 26, 2024 | 6,142 |  |  | $ | 92.57 |
Granted | 4,207 |  |  | 82.37 |
Vested | (2,068) |  |  | 99.19 |
Forfeited/Cancelled | (636) |  |  | 88.62 |
Nonvested at April 25, 2025 | 7,644 |  |  | 85.64 |
The following table summarizes the weighted-average grant date fair value of restricted stock granted, total fair value of restricted stock vested and related tax benefit during fiscal years 2025, 2024, and 2023:
| Fiscal Year
(in millions, except per share data) | 2025 |  | 2024 |  | 2023
Weighted-average grant-date fair value per restricted stock | $ | 82.37 |  |  | $ | 82.80 |  |  | $ | 91.83 |
Fair value of restricted stock vested | 205 |  |  | 186 |  |  | 256 |
Tax benefit related to restricted stock vested | 33 |  |  | 29 |  |  | 45 |
Unrecognized compensation expense related to restricted stock as of April 25, 2025 was $414 million and is expected to be recognized over a weighted average period of 2.6 years. Performance Share Units Performance share units typically cliff vest after three years. The awards include three metrics: relative total shareholder return (rTSR), revenue growth, and return on invested capital (ROIC). rTSR is considered a market condition metric, and the expense is determined at the grant date and will not be adjusted even if the market condition is not met. Revenue growth and ROIC are considered performance metrics, and the expense is recorded over the performance period, which will be reassessed each reporting period based on the probability of achieving the various performance conditions. The number of shares earned at the end of the three-year period will vary, based on only actual performance, from 0% to 200% of the target number of performance share units granted. Performance share units are subject to forfeiture if employment terminates prior to the lapse of the restrictions. Performance share units are not considered issued or outstanding ordinary shares of the Company. Dividend equivalent units are accumulated on performance share units for each component of the award during the vesting period. The Company calculates the fair value of the performance share units for each component individually. The fair value of the rTSR metric will be determined using the Monte Carlo valuation model. The fair value of the revenue growth and ROIC metrics are equal to the closing stock price on the grant date. The following table summarizes performance share unit activity during fiscal year 2025:
| Units (in thousands) |  | Wtd. Avg. Grant Price
Nonvested at April 26, 2024 | 2,422 |  |  | $ | 106.50 |
Granted | 1,444 |  |  | 98.49 |
Vested | (260) |  |  | 147.85 |
Performance adjustments (1) | (256) |  |  | 97.75 |
Forfeited/Cancelled | (209) |  |  | 103.56 |
Nonvested at April 25, 2025 | 3,141 |  |  | 100.51 |
(1)Performance adjustments are adjustments to grants where the performance period has ended and actual performance is known. The following table summarizes the weighted-average grant date fair value of performance share units granted, total fair value of performance share units vested and related tax benefit during fiscal year 2025, 2024, and 2023:
| Fiscal Year
(in millions, except per share data) | 2025 |  | 2024 |  | 2023
Weighted-average grant-date fair value per performance share units | $ | 98.49 |  |  | $ | 104.78 |  |  | $ | 98.17 |
Fair value of performance share units vested | 38 |  |  | 78 |  |  | — |
Tax benefit related to performance share units vested | 3 |  |  | 3 |  |  | — |
Unrecognized compensation expense related to performance share units as of April 25, 2025 was $90 million and is expected to be recognized over a weighted average period of 1.6 years. Employees Stock Purchase Plan (ESPP) The Medtronic plc 2024 Employee Stock Purchase Plan allows participating employees to purchase the Company's ordinary shares at a discount through payroll deductions. The expense recognized for shares purchased under the Company’s ESPP is equal to the 15 percent discount the employee receives. Employees purchased 3 million shares at an average price of $72.27 per share in fiscal year 2025. At April 25, 2025, approximately 26 million ordinary shares were available for future purchase under the ESPP.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration